SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following a preliminary business update that revealed record-breaking demand and a massive order backlog, effectively silencing concerns over weakening margins. The market is buzzing with speculation about a potential short squeeze, as bullish investors highlight the company's improved profitability and expanding AI infrastructure footprint while bearish traders question the management's credibility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Investors are closely monitoring Alphabet ahead of its upcoming earnings report, with community sentiment largely focused on the sustainability of massive AI capital expenditures and their impact on cloud growth. Debate persists over whether the stock will face significant volatility due to high expectations for AI monetization or remain a long-term powerhouse in the tech sector.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is trending following a better-than-expected earnings report that highlighted record fiber and fixed wireless subscriber growth, easing investor concerns regarding potential market disruption from competitors like SpaceX. The community is actively discussing the company's role as a foundational infrastructure play for the AI era and debating the sustainability of its dividend and share repurchase plans against broader sector volatility.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors react to reports of Microsoft deploying the company's new Helios AI infrastructure, fueling speculation about potential major partnerships with Anthropic ahead of a high-profile AI event. The community remains divided, with many debating if current valuations and aggressive expansion plans are sustainable or if the stock is overextended following a significant pre-earnings rally.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is trending as the market evaluates a mixed earnings report, where a bottom-line EPS miss was overshadowed by raised revenue guidance and surging data center demand. Investors are actively debating whether the stock's recent pullback is an overreaction to profit-taking or a necessary correction given the stock's high valuation and technical setup.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is currently a focal point for investors weighing its long-term potential as an AI data licensing platform against concerns regarding traffic sustainability and potential friction with search engine partners. The community remains deeply divided, with bulls pointing to robust growth in self-service advertising and unique human-generated data, while bears caution against overvaluation and the risk of traffic volatility.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is trending as investors focus on its strong government ties and strategic role in quantum sensing for national security and critical minerals mapping. The community is actively discussing the stock's potential for organic growth and long-term value, with many viewing the current price action as a major buying opportunity despite broader market volatility.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a major focal point for investors as they look ahead to upcoming Phase 3 clinical data for ivonescimab, which the community sees as a potential blockbuster in oncology. Conversations are dominated by debates over global trial outcomes and the stock's positioning as a high-stakes disruptor, with active discussions surrounding recent insider buying signals and heavy short interest.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following positive Phase 3 topline results for plozasiran in patients with severe hypertriglyceridemia, which demonstrated significant triglyceride reduction and a clear safety profile. Community discussion is heavily focused on the drug's blockbuster potential, the competitive landscape regarding other industry players, and excitement surrounding the company's robust pipeline and future catalysts.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is seeing massive, record-breaking trading volume driven by bullish sentiment surrounding new defense orders and growing institutional interest. The community is actively discussing the stock's potential for a short squeeze, citing high short interest and anticipation for upcoming earnings to validate the company's long-term growth story.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MNPR Stock Rallies After Hours As Experimental Drug Shows Rapid Copper Balance Improvement In Genetic Disorder 

Equity

The open-label trial showed the drug helped the body remove excess copper more effectively and quickly, mainly by increasing copper excretion through stool.

Monopar Therapeutics (MNPR) Expected to Announce Earnings on Tuesday

Monopar Therapeutics (NASDAQ:MNPR) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-monopar-therapeutics-inc-stock...

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have earned a consensus recommendation of "Buy" from the thirteen research firms that are presently covering the stock, MarketBeat...

Monopar Therapeutics (NASDAQ:MNPR) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded Monopar Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday...

Brookline Capital Markets Forecasts MNPR Q1 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at Brookline Capital Markets increased their Q1 2026 EPS estimates for Monopar Therapeutics in a research report...

HC Wainwright Brokers Reduce Earnings Estimates for MNPR

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright lowered their Q1 2026 EPS estimates for Monopar Therapeutics in a report issued on Monday, March 30th. HC...

Chardan Capital Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)

Chardan Capital reaffirmed a "buy" rating and issued a $100.00 price target on shares of Monopar Therapeutics in a research note on Monday...

Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) announced its earnings results on Friday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Rating of "Buy" from Analysts

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has been given a consensus rating of "Buy" by the thirteen analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and two have is...

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Monopar Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.66	--	--	N/A
Q1 '26	-$0.44	-$0.46	-3.53%	MISSED
Q4 '25	-$0.47	-$0.64	-37.63%	MISSED
Q3 '25	-$0.49	-$0.48	1.16%	BEAT
Q2 '25	-$0.43	-$0.35	19.23%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

MNPRMonopar Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest MNPR News